McKenna Velchek, PA
Physician Assistant · Franklin, INNPI 1336766310
Payments from drug & device makers
Across 337 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$845
- Lilly USA, LLC$533
- Amgen$520
- Corcept Therapeutics$365
- AstraZeneca$217
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,850100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $1,096 |
| AbbVie | 53 | $845 |
| Lilly USA, LLC | 29 | $533 |
| Amgen | 40 | $520 |
| Corcept Therapeutics | 23 | $365 |
| AstraZeneca | 8 | $217 |
| Exact Sciences | 10 | $195 |
| Pfizer | 11 | $189 |
| Averitas Pharma Inc. | 3 | $157 |
| Dexcom, Inc. | 7 | $152 |
| GSK | 9 | $144 |
| Xeris Pharmaceuticals, Inc. | 7 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
| Astellas Pharma US Inc | 5 | $105 |
| Novartis | 5 | $97 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Boehringer Ingelheim | 5 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $89 |
| Axsome Therapeutics, Inc. | 4 | $85 |
| Tandem Diabetes Care, Inc. | 5 | $83 |
| Bayer | 4 | $75 |
| Merck | 3 | $53 |
| Almatica Pharma LLC | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Medtronic | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| IBSA Pharma Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Corium, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$125
- Qutenza$121
- RYBELSUS$115
- FARXIGA$106
- BEVESPI AEROSPHERE$106
How this compares
$5,865 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $71,969 |
| JardianceEmpagliflozin | 58 | $55,325 |
| MounjaroTirzepatide | 53 | $53,736 |
| FarxigaDapagliflozin Propanediol | 42 | $33,637 |
| EliquisApixaban | 23 | $33,409 |
| TrulicityDulaglutide | 31 | $30,238 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,198 |
| GemtesaVibegron | 24 | $20,984 |
| RybelsusSemaglutide | 16 | $20,287 |
| Repatha SureclickEvolocumab | 32 | $20,188 |
| WegovySemaglutide | 12 | $16,886 |
| XareltoRivaroxaban | 20 | $8,601 |
| MyrbetriqMirabegron | 14 | $6,945 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $4,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,096 | $109,14197 claims |
| Lilly USA, LLCMounjaro, Trulicity | $533 | $83,97584 claims |
| PfizerEliquis, Nurtec Odt, Levoxyl | $189 | $56,61649 claims |
| Boehringer IngelheimJardiance | $91 | $55,32558 claims |
| AstraZenecaFarxiga | $217 | $33,63742 claims |
| GSKTrelegy Ellipta | $144 | $21,19825 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $94 | $20,98424 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $6,94514 claims |
| AbbVieSynthroid | $845 | $1,92132 claims |
| Almatica Pharma LLCSertraline Hcl | $51 | $747109 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $25 | $60729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Franklin
- Kristen GumpfCarmel$142K
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lauren HoweMunster$28K
- A FergusonFort Wayne$22K
- Jacquelyn BeemerFort Wayne$21K
- Lindsay YoderIndianapolis$21K
- Eryn GormanClinton$18K
- Audrey HewittBloomington$17K
- Mackenzie LawsonIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.